September 28th, 2020 | 10:15 CEST
BioNTech, NEL ASA, Silver Viper: Profit lies in purchasing
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Investors enable growth
The Canadian company Silver Viper has seen a significant performance in its share price over the past 12 months. In connection with a financing round from 2019, the company can now hope for a further inflow of up to CAD 2.8 million. The financing included an early conversion right of warrants as soon as the share price trades at an average of at least CAD 0.70 for ten consecutive days. This condition was met on 15 September 2020 and the holders of the warrants now have until 8 October to subscribe for the new shares.
"I am very proud of the progress our team has made over the last year. The financing last September was done at 25 cents and we recently hit an all-time high of 85 cents," stated Steve Cope, CEO of Silver Viper and continued: "The majority of the La Virginia project has never seen any modern exploration and we will continue to not only expand on our discoveries at El Rubi but also continue to test the other drill-ready anomalies that we have identified through our surface mapping and sampling programs. With a number of catalysts expected before the end of the year, we fully expect to continue to add value to the company. I would like to thank all of our shareholders for their continued support."
Hydrogen for the ecosystem
The Norwegian plant manufacturer NEL ASA is now one of the best-known suppliers to the global hydrogen ecosystem. In recent years, investors have enabled the company to grow in several financing rounds. From a penny stock, the value of the share peaked at over EUR 2.15.
Currently, the shares are changing hands at around 1.45 EUR. Despite political support with government funding, there has been profit-taking in recent weeks. The fear of further restrictions in the fight against the Corona Pandemic is causing general concern. The decline in the share price may offer an entry opportunity.
Development in full swing
The BioNTech share offers investors the opportunity to participate in a vaccine producer. The German company receives government funding and is considered one of the world's leading pharmaceutical teams in the fight against Covid-19. BioNTech recently acquired production facilities with 300 employees from Novartis.
All areas of the company are geared towards success. It seems that it will not be long before approval is granted. BioNTech is already valued at over USD 15 billion, but as infection rates rise, the need for vaccination will continue to increase. For politicians and industry, the provision of a vaccine will be the end of the restrictions.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.